Mohammed Shurrab1,2, Eugene Crystal3, Denis O'Donnell4, Hrishikesh Navare4, Paula Neves5, Rasha Khatib6, Ilan Lashevsky3, David Newman3. 1. Arrhythmia Services, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Room E241, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada. shurrabm@hotmail.com. 2. Arrhythmia Services, Cardiology Department, An-Najah National University Hospital, Faculty of Medicine and Health Sciences, Nablus, Palestine. shurrabm@hotmail.com. 3. Arrhythmia Services, Schulich Heart Centre, Sunnybrook Health Sciences Centre, University of Toronto, Room E241, 2075 Bayview Avenue, Toronto, ON, M4N 3M5, Canada. 4. Medical Pharmacies Group Limited, Toronto, ON, Canada. 5. Extendicare, Toronto, ON, Canada. 6. Population Health Research Institute, Hamilton Health Sciences, McMaster University, Hamilton, ON, Canada.
Abstract
PURPOSE: The use of oral anticoagulation (OAC) in the elderly population with atrial fibrillation (AF) treated in long-term care (LTC) facilities is inconsistent. We examined the magnitude and sources of the gap between indicated and prescribed OAC in the elderly population with AF. METHODS: We retrospectively scanned the electronic medical record (EMR) and pharmacy data of 25 LTC facilities in Ontario, Canada. The diagnosis of AF was drawn from EMR. Different attributable risk factors for possible failure to prescribe OAC were examined. RESULTS: In total, 3378 active resident data were examined in the 25 LTC facilities. All the residents were ≥65 years old with mean age of 85 ± 8 years and 2449 (72%) were female. We identified 433 (13%) residents with AF with mean age 87 ± 7 years and mean CHADS2 score of 3 ± 1. Out of all residents with AF, 273 (63%) were on OAC therapy. Residents were mostly treated with warfarin (N = 114 (42%)), rivaroxaban (N = 71 (26%)) or apixaban (N = 62 (23%)) followed by dabigatran (N = 26 (10%)). Antiplatelet drugs as the only stroke prevention therapy were used in 88 (20%) residents, and 28 (6%) residents were on anticoagulation and antiplatelet drugs. Seventy-two (17%) residents were not on any antiplatelet or antithrombotic therapy. None of the potential attributable risks identified consistently correlated with the failure to prescribe indicated therapy. CONCLUSIONS: This data set suggests that 37% of eligible elderly LTC residents failed to receive recommended stroke prevention therapies.
PURPOSE: The use of oral anticoagulation (OAC) in the elderly population with atrial fibrillation (AF) treated in long-term care (LTC) facilities is inconsistent. We examined the magnitude and sources of the gap between indicated and prescribed OAC in the elderly population with AF. METHODS: We retrospectively scanned the electronic medical record (EMR) and pharmacy data of 25 LTC facilities in Ontario, Canada. The diagnosis of AF was drawn from EMR. Different attributable risk factors for possible failure to prescribe OAC were examined. RESULTS: In total, 3378 active resident data were examined in the 25 LTC facilities. All the residents were ≥65 years old with mean age of 85 ± 8 years and 2449 (72%) were female. We identified 433 (13%) residents with AF with mean age 87 ± 7 years and mean CHADS2 score of 3 ± 1. Out of all residents with AF, 273 (63%) were on OAC therapy. Residents were mostly treated with warfarin (N = 114 (42%)), rivaroxaban (N = 71 (26%)) or apixaban (N = 62 (23%)) followed by dabigatran (N = 26 (10%)). Antiplatelet drugs as the only stroke prevention therapy were used in 88 (20%) residents, and 28 (6%) residents were on anticoagulation and antiplatelet drugs. Seventy-two (17%) residents were not on any antiplatelet or antithrombotic therapy. None of the potential attributable risks identified consistently correlated with the failure to prescribe indicated therapy. CONCLUSIONS: This data set suggests that 37% of eligible elderly LTC residents failed to receive recommended stroke prevention therapies.
Entities:
Keywords:
Atrial fibrillation; Care gap; Geriatric; Oral anticoagulation
Authors: Atul Verma; John A Cairns; L Brent Mitchell; Laurent Macle; Ian G Stiell; David Gladstone; Michael Sean McMurtry; Stuart Connolly; Jafna L Cox; Paul Dorian; Noah Ivers; Kori Leblanc; Stanley Nattel; Jeff S Healey Journal: Can J Cardiol Date: 2014-08-13 Impact factor: 5.223
Authors: Paul Angaran; Paul Dorian; Mary K Tan; Charles R Kerr; Martin S Green; David J Gladstone; L Brent Mitchell; Carl Fournier; Jafna L Cox; Mario Talajic; Peter J Lin; Anatoly Langer; Lianne Goldin; Shaun G Goodman Journal: Can J Cardiol Date: 2015-10-15 Impact factor: 5.223
Authors: Tommy Andersson; Anders Magnuson; Ing-Liss Bryngelsson; Ole Frøbert; Karin M Henriksson; Nils Edvardsson; Dritan Poçi Journal: Int J Cardiol Date: 2014-10-11 Impact factor: 4.164
Authors: Janet E Squires; Danielle Cho-Young; Laura D Aloisio; Robert Bell; Stephen Bornstein; Susan E Brien; Simon Decary; Melissa Demery Varin; Mark Dobrow; Carole A Estabrooks; Ian D Graham; Megan Greenough; Doris Grinspun; Michael Hillmer; Tanya Horsley; Jiale Hu; Alan Katz; Christina Krause; John Lavis; Wendy Levinson; Adrian Levy; Michelina Mancuso; Steve Morgan; Letitia Nadalin-Penno; Andrew Neuner; Tamara Rader; Wilmer J Santos; Gary Teare; Joshua Tepper; Amanda Vandyk; Michael Wilson; Jeremy M Grimshaw Journal: CMAJ Date: 2022-02-28 Impact factor: 16.859